Analyst Insights - Digital Health Posts

Read our Analysts’ insights and expert opinions on the latest healthcare technology industry developments and market trends. Signify Research provides both free insights and premium insights which are only available to subscribers of "Signify Premium Insights".
Click on the premium insights link below to filter for just the premium content.



Signify Premium Insight: Fujifilm and Hitachi – The Pieces of a Puzzle

Signify Premium Insights Subscription Required

March 4th 2021 – Fujifilm has announced that its acquisition of Hitachi’s imaging division is set to close at the end of March. This Insight looks at what Fujifilm is actually getting, and how it might help its strategy going forward.

EHR Q4 2020 Financials Highlight Mixed Regional Trends in 2020

4th March 2021 – With Q4 2020 revenue data now published for several leading EHR vendors, Signify Research compares its 2020 estimates versus these public financials.

Signify Premium Insight: The Options for Watson

Signify Premium Insights Subscription Required

March 2nd 2021 – IBM, and its plan to use AI to solve some of the biggest problems in healthcare, made headlines when it first announced its Watson Health division. Now however, the company is reportedly looking to sell the unit. This insight considers what’s changed to assess the rumours.

AI in Drug Development & Clinical Trials Market to Reach $3.0 Billion by 2024

25th February 2021 – The world market for AI used in drug development and clinical trials is set to reach almost $3.0 billion by 2024. This is according to a new report from Signify Research, an independent supplier of market intelligence and consultancy to the global healthcare technology industry.

Signify Premium Insight: Intelerad Acquires LumedX – Now the Work Begins

Signify Premium Insights Subscription Required

February 25th 2021 – News broke last week that imaging IT vendor Intelerad has acquired LumedX, the latest in a rapid-fire acquisition streak from the imaging IT vendor, In this Insight we analyse the implications of the acquisition for the firms and postulate to the drivers and market context that have led to the deal.